CLINICAL TRIALS PROFILE FOR VENETOCLAX

505(b)(2) Clinical Trials for venetoclax

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT04599634 ↗	Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies	Not yet recruiting	National Cancer Institute (NCI)	Phase 1	2021-11-16	Background: B-cell lymphoma is a cancer of certain white blood cells (called lymphocytes). These cells are found in lymph nodes. The cancer can cause enlargement of the lymph nodes leading to pain and discomfort. Swollen lymph nodes can also press on nearby organs such as liver and kidneys which can affect normal functioning of the organs. Researchers think that a new combination of drugs may be able to help. Objective: To find out if it is safe to give the combination of Magrolimab, Obinutuzumab and Venetoclax to people with B-cell lymphomas. Eligibility: Adults age 18 and older with an indolent B-cell lymphoma whose disease has returned or progressed after other treatment. Indolent B-cell lymphoma for this protocol is defined as having either follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma or marginal zone lymphoma. Design: Participants will be screened under a separate protocol. Participants will have 28-day 'cycles' of treatment. They will take Venetoclax by mouth daily. They will get Obinutuzumab and Magrolimab by intravenous (IV) infusion. Treatment will last for about 8 months. They may be able to have more cycles of treatment if their cancer is responding well. Participants will have physical exams, medical histories, and medicine reviews. Data about how they function in their daily activities will be obtained. They will have blood and urine tests. They may have bone marrow tests. Participants will have imaging scans. These will include computed tomography (CT) and/or magnetic resonance imaging (MRI) scans and positron emission tomography (PET) scans. Participants may give a cheek swab or saliva sample. They may give tumor tissue and bone marrow samples. These samples may be used for gene testing. Participants will have a follow-up visit about 30 days after treatment ends. Then they will have visits every 3 months for the first 2 years, every 6 months for the next 3 years, and then yearly after that.

All Clinical Trials for venetoclax

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00501826 ↗	Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma	Recruiting	GlaxoSmithKline	Phase 2	2007-07-11	This phase II trial studies the side effects and how well combination chemotherapy and nelarabine work in treating patients with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, mercaptopurine, prednisone, pegaspargase, nelarabine, and venetoclax work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
NCT00501826 ↗	Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma	Recruiting	National Cancer Institute (NCI)	Phase 2	2007-07-11	This phase II trial studies the side effects and how well combination chemotherapy and nelarabine work in treating patients with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, mercaptopurine, prednisone, pegaspargase, nelarabine, and venetoclax work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
NCT00501826 ↗	Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma	Recruiting	M.D. Anderson Cancer Center	Phase 2	2007-07-11	This phase II trial studies the side effects and how well combination chemotherapy and nelarabine work in treating patients with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, mercaptopurine, prednisone, pegaspargase, nelarabine, and venetoclax work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
NCT01211457 ↗	Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)	Unknown status	M.D. Anderson Cancer Center	Phase 1/Phase 2	2010-06-17	This is a combination study to evaluate sapacitabine administered in alternating cycles with decitabine in previously untreated Acute Myeloid Leukemia (AML) or concomitantly with venetoclax in previously treated AML or MDS
NCT01211457 ↗	Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)	Unknown status	Cyclacel Pharmaceuticals, Inc.	Phase 1/Phase 2	2010-06-17	This is a combination study to evaluate sapacitabine administered in alternating cycles with decitabine in previously untreated Acute Myeloid Leukemia (AML) or concomitantly with venetoclax in previously treated AML or MDS
NCT01671904 ↗	A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)	Completed	AbbVie (prior sponsor, Abbott)	Phase 1	2014-01-13	This multi-center, open-label, dose-finding study will evaluate the safety and pharmacokinetics of venetoclax (GDC-0199, ABT-199) administered in combination with bendamustine and rituximab (BR) (MabThera/Rituxan) or bendamustine and obinutuzumab (BG) to participants with first-line (1L)/previously untreated or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). The study will explore two venetoclax combination regimens in participants with 1L CLL: BR+venetolax (V) and BG+V. Participants with R/R CLL will be administered BR+V.

Clinical Trial Conditions for venetoclax

Condition Name

Condition Name for venetoclax
Intervention	Trials
Acute Myeloid Leukemia	172
Chronic Lymphocytic Leukemia	60
Refractory Acute Myeloid Leukemia	37
Small Lymphocytic Lymphoma	32

Condition MeSH

Condition MeSH for venetoclax
Intervention	Trials
Leukemia	303
Leukemia, Myeloid, Acute	295
Leukemia, Myeloid	173
Leukemia, Lymphoid	117

Clinical Trial Locations for venetoclax

Trials by Country

Trials by Country for venetoclax
Location	Trials
China	310
Japan	189
Australia	183
France	140
Canada	133

Trials by US State

Trials by US State for venetoclax
Location	Trials
Texas	175
California	115
New York	112
Ohio	93
Massachusetts	89

Clinical Trial Progress for venetoclax

Clinical Trial Phase

Clinical Trial Phase for venetoclax
Clinical Trial Phase	Trials
PHASE4	4
PHASE3	15
PHASE2	113

Clinical Trial Status

Clinical Trial Status for venetoclax
Clinical Trial Phase	Trials
Recruiting	350
Not yet recruiting	135
Active, not recruiting	61

Clinical Trial Sponsors for venetoclax

Sponsor Name

Sponsor Name for venetoclax
Sponsor	Trials
AbbVie	123
National Cancer Institute (NCI)	101
M.D. Anderson Cancer Center	72

Sponsor Type

Sponsor Type for venetoclax
Sponsor	Trials
Other	774
Industry	398
NIH	103

Venetoclax (Venclexta): Clinical Trials Update and Market Outlook

Last updated: April 27, 2026

Where is Venetoclax in clinical development?

Venetoclax has transitioned from early oncology development into broad, multi-line use across hematologic malignancies, with additional studies focused on combinations, sequencing, and expanded indications. The development pipeline is anchored by the established regulatory footprint in CLL and AML and is supported by active trials in related disease states and treatment settings. The most material near-term clinical signals come from ongoing combination regimens and label-enabling studies across CLL, SLL, and AML subtypes.

Core approved use as the anchor for ongoing trials

• Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
  Venetoclax has an approved position in CLL and SLL, including time-limited regimens in combination strategies.
• Acute myeloid leukemia (AML)
  Venetoclax has an approved backbone in combination with hypomethylating agents and low-dose cytarabine in treatment settings reflected in current labeling.

Trial update themes that drive incremental value

• Finite-duration regimens in CLL/SLL: Ongoing trials continue to refine dosing schedules and partner selection with BTK inhibitors and anti-CD20 antibodies, aiming to sustain deep remissions while limiting time on therapy.
• Relapsed/refractory (R/R) settings: Studies target outcomes after prior lines, often testing venetoclax sequencing against newer agents and combination backbones.
• AML subgrouping and intensity: Trials focus on safety and efficacy stratification by genetic risk and prior exposure, with combination selection calibrated for response durability and MRD behavior.
• Real-world alignment: Registries and pragmatic studies increasingly support dosing optimization and discontinuation rules, which can influence dosing duration and payer behavior.

Regulatory and labeling foundation: Venclexta prescribing information and FDA materials define approved uses and dosing logic that shape trial endpoints and expected uptake pathways. Source: FDA and product label. [1], [2]

What is the current commercial market position?

Venetoclax is a high-revenue oncology small molecule with a concentrated franchise tied to CLL/SLL and AML. Commercial momentum is shaped by:

• Line-of-therapy penetration driven by improved efficacy profiles
• Combination standardization with partner drugs that reduce time to adoption
• Duration-of-treatment economics in CLL, where time-limited strategies can compress total drug exposure even as patient access expands

Pricing and access mechanics that influence demand

• Combination regimens can raise total regimen intensity but can accelerate adoption when they improve depth and durability.
• Duration-limited regimens in CLL can reduce per-patient venetoclax exposure over time, creating a volume-over-dollar dynamic: growth depends on incident and eligible patient counts plus switching behavior.
• Payer controls typically hinge on molecular criteria, treatment line, and co-administered regimen components.

Label-led dosing framework: Venclexta has a ramp-up dosing strategy in oncology use and established monitoring guidance, including tumor lysis risk management, which affects real-world administration and may influence early adoption in certain settings. Source: Venclexta prescribing information. [2]

How should investors and R&D leaders project future demand?

Projection logic for venetoclax should be built on four demand drivers and two risk levers.

Demand drivers

1. CLL/SLL patient pool expansion through combinations
   Combination regimens and improved sequencing can expand eligible populations beyond older historical adoption constraints.
2. AML regimen reinforcement in older/unfit populations
   Venetoclax combinations in AML remain a benchmark for efficacy in patient subsets that can tolerate the combination strategy.
3. Time-limited adoption rules in CLL/SLL
   If trials confirm high response rates with finite durations, clinicians and payers can treat venetoclax as a predictable, guideline-aligned regimen rather than a continuing therapy.
4. Competition mapping and regimen substitution
   Uptake continues to depend on whether newer agents shift physician preference away from venetoclax-based backbones or whether venetoclax maintains a durable response advantage that supports standard-of-care status.

Risk levers

1. Safety management and discontinuation
   Tumor lysis risk management and infection risk can constrain uptake in frailer patients; regimen modifications may impact dose intensity.
2. Clinical differentiation vs next-generation BCL2-adjacent strategies
   Newer apoptosis pathway agents or next-generation BCL2 inhibitors could pressure share if they deliver similar efficacy with improved tolerability.

Projection approach (baseline framework)

Because the input prompt does not provide numeric market-size baselines, the most decision-useful projection format here is an actionable scenario model structure that links clinical assumptions to commercial outcomes:

Scenario	Key clinical assumption	Uptake effect	Revenue effect
Base	CLL/SLL and AML maintain label-reinforced standard use; time-limited CLL regimens stabilize	Moderate volume growth, stable conversion	Flattish net pricing offset by modest demand growth
Upside	Combination regimens broaden eligibility; finite-duration protocols reduce discontinuations and improve adherence	Faster penetration and higher eligible-line treatment	Growth from higher treated population outweighs duration compression
Downside	Safety constraints and competitive substitution accelerate; AML partner shifts reduce venetoclax centrality	Slower penetration	Reduced demand with limited offset from regimen expansion

Commercial sensitivity points

• Treatment duration in CLL: a direct lever on per-patient venetoclax tablets and total dose delivered.
• Switching behavior after prior targeted therapy: impacts R/R growth rate.
• Partner drug utilization: venetoclax demand is coupled to the adoption path of BTK inhibitors, anti-CD20 antibodies, and AML hypomethylating agent backbones.

What are the most decision-relevant policy and regulatory signals?

FDA label and risk framework drives adoption

The label includes a tumor lysis syndrome (TLS) risk management framework and structured dosing/ramp guidance. Clinicians often adopt only after internal protocols exist for prophylaxis and monitoring. This can create regional adoption lags even with high clinical efficacy. Source: FDA and Venclexta prescribing information. [1], [2]

Oncology trial endpoints and reimbursement behavior

Oncology payer coverage tends to track:

• Line-of-therapy requirements
• Combination regimen restrictions
• Genetic or disease-status qualifiers where relevant
• Clinical response endpoints translating into durable benefit claims

These factors shape how quickly trial results convert into commercial uptake.

Clinical trial landscape: what should be tracked next?

For an actionable “what matters now” monitoring list, the focus should be on:

• Durable response endpoints in CLL/SLL with time-limited strategies (deep response durability and MRD-related outcomes)
• AML subgroup readouts that confirm benefit by genetic risk profile and prior exposure patterns
• Safety updates that influence dosing intensity and discontinuation in the real-world setting
• Sequence comparisons versus evolving standard-of-care regimens to determine switch risk

These endpoints typically drive guideline inclusion, payer policy updates, and formulary placement cadence.

---

Key Takeaways

• Venetoclax’s near-term value growth depends on CLL/SLL and AML expansion through combination regimens and on how time-limited CLL protocols affect per-patient dosing economics.
• The commercial trajectory is most sensitive to treatment duration in CLL, eligibility expansion, and switching patterns in R/R lines.
• Investors should monitor trial readouts tied to durability, safety management, and sequencing because these determine guideline adoption speed and payer coverage behavior.
• Regulatory dosing and TLS risk management in the label influence real-world adoption lags and can constrain early uptake in settings without mature prophylaxis workflows.

---

FAQs

1) What cancers does venetoclax target commercially?
Venetoclax is used in CLL/SLL and AML, supported by established FDA-labeled dosing and combination frameworks. [1], [2]

2) Why do combinations matter for venetoclax demand?
Venetoclax demand is driven by partner regimen adoption because it is typically used in combination regimens that define eligibility and standard-of-care pathways. [2]

3) How does time-limited therapy in CLL affect revenue projection?
Time-limited use can reduce per-patient venetoclax exposure, so revenue growth relies more on patient volume and eligibility than on continued dosing duration.

4) What is the biggest adoption constraint implied by the label?
The label’s tumor lysis syndrome risk management and dosing ramp structure can affect real-world uptake speed depending on how quickly clinical sites implement TLS protocols. [2]

5) What trial results would likely have the biggest commercial impact?
Readouts that confirm durable responses, safety sufficient for broader eligibility, and clear sequencing advantages versus current standards tend to drive adoption and payer positioning. [2]

---

References (APA)

[1] U.S. Food & Drug Administration. (n.d.). FDA approval and label information for Venclexta (venetoclax). https://www.fda.gov/
[2] AbbVie Inc. & Genentech, Inc. (n.d.). Venclexta (venetoclax) prescribing information. https://www.accessdata.fda.gov/